Zydus Lifesciences LimitedNSE: ZYDUSLIFE

Press Release Aug 04 2022

· Issued by Zydus Lifesciences Limited

Filed with NSE · · 3 pages · English

Summary by 6ix AI

This filing is a press release from Zydus Lifesciences Limited reporting two final approvals from the USFDA for new products. The first approval is for Ivermectin Cream, which is used to treat rosacea and will be manufactured in Ahmedabad.

Written by 6ix AI from the company’s filing. How 6ix writes summaries

Release

Zydus Lifesciences Limited has informed the Exchange about press release dated 04-Aug-2022 titled Zydus receives final approval from the USFDA for Ivermectin Cream and Zydus receives final approval from the USFDA for Empagliflozin Tablets

Zydus Lifesciences Limited on 6ix

Earlier from Zydus Lifesciences

Later from Zydus Lifesciences

All Zydus Lifesciences news releases